MedWatch - The FDA Safety Information and Adverse Event Reporting Program
FDA notified healthcare professionals and consumers of new safety information regarding taking medications used to treat migraine headaches (triptans) together with certain types of antidepressant and mood disorder medications (selective serotonin reuptake inhibitors
(SSRIs) and selective serotonin/norepinephrine reuptake inhibitors (SNRIs)
A life-threatening condition called serotonin syndrome may occur when triptans are used together with a SSRI or a SNRI. Serotonin syndrome occurs when the body has too much of a chemical found in the nervous system (serotonin). Each of the above medications (triptans, SSRIs, and SNRIs), cause an increase in serotonin levels. Symptoms of serotonin syndrome may include restlessness, hallucinations, loss of coordination, fast heart beat, rapid changes in blood pressure, increased body temperature, overactive reflexes, nausea, vomiting, and diarrhea.
Healthcare professionals prescribing a triptan, SSRI or SNRI should 1) keep in mind that triptans are often used intermittently and either the triptan, SSRI or SNRI may be prescribed by a different physician; 2) weigh the potential risk of serotonin syndrome with the expected benefit of using the above combination; 3) discuss the possibility of serotonin syndrome with patients if a triptan and an SSRI or SNRI will be used together; and 4) follow patients closely during treatment if a triptan and an SSRI or SNRI are used together.
Patients taking a triptan along with an SSRI or SNRI should talk to their doctor before stopping their medication and should immediately seek medical attention if they experience any of the above symptoms.
The FDA requested that all manufacturers of triptans, SSRIs and SNRIs update their prescribing information to warn of the possibility of serotonin syndrome when these medications are taken together.
Read the complete MedWatch 2006 Safety summary, including links to the FDA Public Health Advisory at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#Triptans
More Med Watch:
Promethazine Contraindicated in Children Younger Than Two All products containing promethazine, both brand name and generic, are contraindicated in children younger than two because the drug could cause fatal respiratory depression...http://www.accessdata.fda.gov/psn/transcript.cfm?show=53#1
Novartis (FFF) implements procedure for return of Fluvirin for Federal Excise Tax credit
Safety Recommendations for Baxter Colleague Infusion Pumps FDA is recommending that users of Colleague pumps take certain safety steps... http://www.accessdata.fda.gov/psn/transcript.cfm?show=53#2
Generic Acetaminophen Recalled for Labeling Error The distributor IVAX Pharmaceuticals is recalling certain lots of 500 mg Goldline brand acetaminophen tablets and capsules...http://www.accessdata.fda.gov/psn/transcript.cfm?show=53#6
Paxil and Increased Risk of Suicidality in Young Adults GlaxoSmithKline is notifying healthcare professionals about new suicidality warnings for adult patients, especially those aged 18 to 24...http://www.accessdata.fda.gov/psn/transcript.cfm?show=53#7
FDA Announces that Companies Must Stop Marketing Suppository Products Containing Trimethobenzamide
FDA PRESS RELEASE
FOR IMMEDIATE RELEASE
April 6, 2007
P07-59
Media Inquiries: 301-827-6242
Press Officer: Kimberly Rawlings
Kimberly.rawlings@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA
U.S. drugs have required marketing approval, the agency announced today that companies must stop manufacturing and distributing unapproved suppository drug products containing trimethobenzamide hydrochloride. These products are used to treat nausea and vomiting in adults and children. Drugs containing trimethobenzamide in suppository form lack evidence of effectiveness. These products have been marketed under various names, including Tigan, Tebamide, T-Gen, Trimazide, and Trimethobenz.
FDA urges consumers who are using suppositories containing trimethobenzamide, and who have questions or concerns, to contact their health care provider. There are many alternative products approved to effectively treat nausea and vomiting, and that are available in a variety of forms, including tablets, capsules, solutions, injectables and suppositories. Several oral capsules and injectable products containing trimethobenzamide have been approved by FDA and are not affected by today’s action.
“FDA is continuing its work to remove unapproved drugs from the market,” said Steven Galson, M.D., M.P.H., director of FDA’s Center for Drug Evaluation and Research (CDER). “FDA is committed to ensuring that the medicines Americans rely on when they are sick are proven to be effective and safe.”
http://www.fda.gov/OHRMS/DOCKETS/98fr/78n-0224-nwl0002.pdf which outlines the agency’s order to manufacturers and distributors, also concludes all outstanding issues for drugs containing trimethobenzamide, under the Drug Efficacy Study Implementation program (DESI). In 1962, Congress amended the Federal Food, Drug, and Cosmetic Act to require that drugs be shown to be effective, as well as safe. Under DESI, FDA evaluated the evidence of effectiveness for thousands of drug products previously approved for safety only, including those products marketed under the name of Tigan containing trimethobenzamide.
Because DESI findings apply to any unapproved products that are identical, related, or similar to DESI-reviewed drugs, today’s notice makes the marketing of any unapproved trimethobenzamide hydrochloride suppository products unlawful.
“Prescription drugs that have not gone through the FDA approval process are of unproven safety and effectiveness,” said director of CDER’s Office of Compliance, Deborah M. Autor. “Today’s action helps ensure that health care providers prescribe, and consumers take, only medicines shown to be effective.”
A small amount of these products will still be available in pharmacies after that date until supplies are exhausted. Any company wishing to market a product containing trimethobenzamide in suppository form must now obtain an approved new drug application prior to marketing.
This action is the next step in a concerted FDA effort to ensure that all marketed U.S. drugs have required FDA approval. In June of last year, FDA announced its renewed emphasis on this issue and sent a clear signal to industry that FDA expects all marketed drugs to have required FDA approval, and that the agency will take action to make that happen. At that time, FDA published a Compliance Policy Guide or CPG, which is a guidance document that describes the agency’s risk-based enforcement approach to marketed unapproved drugs. Completing DESI proceedings is a separate but important part of tackling the unapproved drugs problem.
